Recursion Pharmaceuticals

Home
United States
Salt Lake City, UT
Recursion Pharmaceuticals

Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery and radically improve lives.

Traditional drug discovery methods are inefficient and expensive – approximately 90% of all drugs in clinical trials ultimately fail to get approved and the total investment needed to develop each approved medicine exceeds $2 billion. This inefficiency occurs because biology is extraordinarily complex, and our industry has historically lacked the tools to understand how it functions. At Recursion, we’re harnessing the convergence of multiple breakthrough technologies that allow our scientists to explore uncharted areas of biology and unravel its complexity to navigate the path to better treatments. We have built a massive proprietary biological and chemical database that predicts trillions of relationships across biology and chemistry, many of which are not known in scientific literature. Our approach generates novel insights, broadens the scope of potential medicines, and truly industrializes drug discovery – increasing the scale, speed and efficiency of each step of the process. We believe our technology and approach has the potential to not only radically improve the lives of patients, but also change the landscape of drug discovery and development forever.

11/26/2025

🚀 Want to work on the cutting edge of AI drug discovery?

We’re looking for an Associate Principal of TechBio Discovery Biology in our Salt Lake City or New York City office.

✨ About the role:

▪️ You’ll be working at the intersection of technology and biology, and play a critical role in defining and executing our oncology strategy, integrating traditional drug discovery principles with cutting-edge computational approaches.

▪️ You’ll lead scientific initiatives focused on successfully delivering various small molecule programs from initial hit to candidate selection and IND submission.

▪️ You’ll contribute to novel target insight generation, patient refinement, and patient selection strategies within several early discovery programs, with the opportunity to improve the Recursion OS itself.

👉 Learn more and apply: https://job-boards.greenhouse.io/recursionpharmaceuticals/jobs/7305184?gh_src=2uzvfbmw1us

11/25/2025

In a new story in STAT, incoming CEO and President Najat Khan, PhD spoke to Andrew Joseph about why she’s confident in building on the company’s progress in Recursion’s next chapter.

On why she’s excited to lead.
“Pairing ambition with discipline is very important. As you scale a company, you can’t do everything. For me, what I’ve always done is impact for patients, and shareholder value.”

On the importance of culture.
“Some people understand AI really well, but they underestimate the complexity of biology and chemistry. Others understand biology and chemistry. But finding people that can speak both languages — I use the word bilingual — is one of the hardest things. That is a culture we have at Recursion.“

About how she’s continuing to position Recursion to win.
“This space is moving incredibly fast. Every day, there’s a new model, new data. We need to keep investing in our platform, but only in areas where we can win. We also have to be disciplined. I think the fact that we reduced operating costs by 35% shows you the kind of discipline that we will continue to have. Every dollar counts. So you’ll see rapid go, no-go decisions. We’re not like a biotech with one or two assets. We have more coming. It’s a portfolio view — what do I think has the best chance?”

Read more: https://www.statnews.com/2025/11/21/recursion-ai-drug-development-najat-khan/

11/24/2025

🚀 The energy and momentum happening around life sciences in London – fueled by innovation and investment in AI – is undeniable.

That momentum was on full display last week at the Jefferies Global Healthcare Conference and London Life Sciences Week presentations and events.

💥 Some highlights:

▪️ Recursion CFO Ben Taylor spoke on the panel: “AI in Life Sciences: Is It All Hype?” where he shared that what gives him hope is how AI is enabling better decision-making. “We have more data. We’re not basing tens of millions of dollars and years of time and patients’ lives off of a couple dozen mice, how they behave, how they react. There is this power that comes out of the data and the analytics that’s informing our decision-making and that really gives me hope.” We’re not just designing drugs, Ben told the audience, we’re creating treatments for specific patient populations, guided by data.

▪️ We also had a great time at the invite-only BACKED VC event, where moderator Yasmin Siraj spoke with Jon Symonds, chair of GSK and Chris Gibson about their personal journeys and lessons learned in discovering, developing and scaling category-defining therapeutics.

▪️ And incoming Recursion CEO and President Najat Khan, PhD spoke at Jefferies about Recursion’s next era and what differentiates us. “We have over 65 petabytes of proprietary data. Every day you see different models being developed,” she said, “but they’re usually trained on the same public data sets…Differentiation comes from having proprietary, high-quality data. We run a couple of million experiments a week. For a 600-person company to have that much data that’s been generated and supporting multiple programs wholly owned and with partnerships, it’s difficult to do unless you also automate and have a wet-lab and dry-lab loop where your models get good enough that it actually predicts which experiments you should do. That’s where the world for discovery and development is going.”

Can’t wait to continue our London conversations and keep the momentum going!

11/21/2025

🧠 How the Microglia Map will help guide new insights and therapeutic pathways for treating neurodegenerative diseases.

In a new story in Technology Networks, incoming CEO and President Najat Khan, PhD shared insights into the creation of the Microglia Map in partnership with Roche and Genentech, and what it could mean for future drug discovery.

▪️ On why this is such a significant breakthrough.

“By performing a whole-genome screen on >17,000 genes, it enables researchers to look at the unexplored biology around the known ‘bright spots,’ driving the discovery of completely novel genes and pathways for first-in-class therapies.”

▪️ On the challenges of producing over 100 billion hiPSC-derived microglia.

“The team had to develop and scale new cell manufacturing techniques in order to produce enough microglia for the map, and to produce them in a standardized way, something that had never been done before. Microglia can be highly variable from batch to batch – and are very sensitive to their environment, changing states from relatively stable to becoming more reactive and inflammatory. The team successfully confirmed that the microglia we started with were as stable as possible, which allowed us to reliably compare all the map perturbations against one another.”

▪️ On what to expect from the Microglia Map.

“There’s a massive need for new targets and new therapies in neurodegenerative diseases and I believe these maps will serve as an important starting place for significantly expanding those opportunities.”

*Learn more: https://www.technologynetworks.com/drug-discovery/blog/mapping-microglia-to-unlock-new-paths-in-neuroscience-407070

11/18/2025

In a new video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts: “What is one thing you wish your families understood about the work that you do?”

For many, it’s all about the patients.

11/17/2025

🎉 Incoming CEO Najat Khan was named one of 2025’s Fiercest Women in Life Sciences from Fierce Pharma.🎉

Each year, the list celebrates women who are making a powerful impact across biopharma and medtech, and have strong track records in innovation, leadership, and mentorship.

Najat has always found ways to break down barriers in her career – from integrating data science at scale at Johnson & Johnson Innovative Medicine to leading the acceleration of the Recursion OS 2.0 into a true end-to-end AI-enabled platform for drug discovery and development. She’s seen firsthand the benefit of merging life sciences and technology disciplines in her own life and is a true believer that the future of medicine lies in this intersection.

“By bringing together AI, biology, chemistry, and clinical science, together with business acumen,” Najat says, “I believe we can fundamentally change how medicines are discovered and developed and deliver innovation that truly changes patients’ lives.”

👉 Read more: https://www.fiercepharma.com/pharma/2025s-fiercest-women-life-sciences

11/13/2025

We’re headed to the Jefferies Global Healthcare Conference & London Life Sciences Week!

Just added - we’re now partnering on a BoltzGen Presentation on Nov. 19, 5-9pm at Recursion’s London office in King’s Cross. Get the latest details on the new BoltzGen model and discuss the future of biomolecular design. Register here (in-person only): https://luma.com/l2zgvfwt

Full events list:

Mon., Nov 17, 11:50am: Future of Life Sciences panel: “AI in Life Sciences: Is It All Hype?” from Knowledge Quarter. At London Life Sciences Week Pavilion. https://
lifesciencesweek.london

Tues., Nov. 18, 10:30am: Jefferies Global Healthcare Conference Fireside Chat. Webcast: https://wsw.com/webcast/jeff332/register.aspx?conf=jeff332&page=rxrx&url=https%3A//wsw.com/webcast/jeff332/rxrx/1900764

Tues., Nov. 18, 3:30pm: London Bio Afternoon Tea with BACKED VC. https://
gatsby.events/backed-vc/rsvp
/register?e=london-bio-london-life-sciences-week-jefferies-2025&ref=speaker

Wed., Nov. 19, 5:00pm: BoltzGen Presentation in partnership with Recursion. https://luma.com/l2zgvfwt

Thurs., Nov 20, 6pm: London Life Sciences Week Knowledge Quarter Closing Event at One Triton Square. https://luma.com/lifesciencewrapparty

See you there!

Learn more: https://
londonandpartners.com/newsroom/news-
and-communications/london-surges-ahead-as-europes-life-sciences-capital

11/12/2025

🔹 Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP).

On Sept. 6, Recursion collaborators in the lab of José Luis Millán, PhD, Professor of the Human Genetics Program at Sanford Children’s Health Research Center, presented a poster on REC-102, Recursion’s oral ENPP1 inhibitor for HPP, a rare genetic disease that causes skeletal and dental hypomineralization at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting. Results of the study – investigating whether inhibiting the enzyme ENPP1 could offer an alternative to current injection-based therapies – have been published in the Journal of Bone and Mineral Research.

REC-102 leveraged AI-enabled precision design capabilities from our platform to optimize for compound properties suitable for chronic dosing, enabling a candidate with potential best-in-class characteristics.

💡 Key takeaways from early preclinical data include:

▪️ Novel Therapeutic Strategy

▪️ Encouraging PPi Reduction In Vivo

▪️ Improved Bone Mineralization

👉 Read the paper: https://academic.oup.com/jbmr/advance-article/doi/10.1093/jbmr/zjaf136/8275834

11/06/2025

🚀 Recursion announced a leadership transition plan to drive the next phase of its growth.

Effective January 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President and Robert Hershberg, Recursion’s current Chairman, will transition to Vice-Chairman and Lead Independent Director.

11/04/2025

Recursion announced today that it will participate in the following upcoming investor conferences:

▪️ Nov. 11, 8 am ET: Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston

▪️ Nov. 18, 10:30 am GMT: Jefferies Global Healthcare Conference in London

👉 Tune in to the webcasts at: ir.recursion.com.

11/03/2025

The making of the world’s first Microglia Map to explore new targets for neurological diseases.

In our latest Explain the Impact video, we share the inside story of the first-of-its-kind Microglia Map from Recursion and Roche and Genentech – including the development of new cell manufacturing techniques to produce over 100 billion microglial cells – and why the field has struggled for so long to expand neuroscience therapies beyond a few well-known targets even though neurological conditions are the #1 cause of illness and disability worldwide.

10/31/2025

👩‍🔬 A new round of Returnship opportunities are now available!

Recursion’s 16-week Returnship Program gives those who have taken a hiatus (2+ years) from the STEM industry the opportunity to return to the workforce, providing hands-on experience on cutting edge tools and technology, along with mentorship and weekly seminars.

🧪 New Returnship roles are now available in: Tissue Culture, Biology Multi-Omics Assay Development; CMC Analysis; CMC Financial; Data Science and Product Management.

Interested? Explore our open Returnship roles here: https://job-boards.greenhouse.io/recursionpharmaceuticals

Address

41 S Rio Grande Street
Salt Lake City, UT
84108

Website

http://www.recursion.com/

Alerts

Be the first to know and let us send you an email when Recursion Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Recursion Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in Salt Lake City?

Our Story

Our dynamic team combines innovative biological science with advanced computational algorithms to discover new therapeutic opportunities for rare genetic diseases. We use high-throughput genetic manipulation to model many diseases in multiple human cell types quickly and efficiently. Thousands of cells representing each model are imaged using high-throughput automated microscopy. We use automated image segmentation systems to quantify hundreds or thousands of structural relationships in tens of thousands of cells for every disease we model. Our proprietary informatics approaches enable us to identify the critical disease-specific changes associated with each disease model. Once we have quantified the phenotypic fingerprint (phenoprint) for a disease, we model it en-masse in thousands of wells and evaluate the ability of thousands of drugs to rescue the disease-specific structural perturbations back to 'health'.